PDCD1 and diffuse large B-cell lymphoma: Some preclinical trials have reported that the therapeutic effects of treatment in patients with EBV+DLBCL can be improved by blocking the PD1/PD-1 cell signaling pathway with anti-PD1 monoclonal antibody [13,14].